Fed. Circ. Upholds Most Patents For Allergan Glaucoma Drug

Law360, New York (May 2, 2013, 3:06 PM EDT) -- The Federal Circuit ruled Wednesday that only one of the four patents for Allergan Inc.'s glaucoma drug Combigan was invalid, partly reversing a lower court’s decision but still preventing Sandoz Inc. and other generic-drug makers from selling their versions of the drug until after the last of the patents expires in 2022.

Several Sandoz units, as well as Apotex Inc. and Watson Laboratories Inc. — which had all been sued by Allergan in 2009 for alleged infringement — had challenged a Texas federal court's ruling that...
To view the full article, register now.